Skip to content
Screener

Halozyme Therapeutics HALO Total Cost of Revenue

Total Cost of Revenue at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$543.1M+10.3%
AMP
Amphastar PharmaceuticalsAMPH
$90.43M+2.9%
AptarGroup logo
AptarGroupATR
$630.96M+14.5%
Opko Health logo
Opko HealthOPK
$83.56M-22.2%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$461.69M+5.3%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$3.47M-5.0%

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Revenues under collaborative agreements43,67438,57049,27757,198
Total revenues480,999325,719857,707590,580
Operating expenses
Cost of sales79,17146,359158,40994,762
Amortization of intangibles29,51217,76259,02435,524
Research and development27,66417,54353,22432,342
Selling, general and administrative56,99841,614114,87983,976
Total operating expenses193,345123,278385,536246,604

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's total cost of revenue?
Halozyme Therapeutics (HALO) reported total cost of revenue of $79.17M in Q2 2026.
How has Halozyme Therapeutics's total cost of revenue changed year-over-year?
Halozyme Therapeutics's total cost of revenue increased by 70.8% year-over-year, from $46.36M to $79.17M.
What is the long-term trend for Halozyme Therapeutics's total cost of revenue?
Over 4 years (2021 to 2025), Halozyme Therapeutics's total cost of revenue has grown at a 29.5% compound annual growth rate (CAGR), from $81.41M to $228.77M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Halozyme Therapeutics's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude